全文获取类型
收费全文 | 839篇 |
免费 | 49篇 |
国内免费 | 3篇 |
专业分类
耳鼻咽喉 | 7篇 |
儿科学 | 8篇 |
妇产科学 | 67篇 |
基础医学 | 117篇 |
口腔科学 | 6篇 |
临床医学 | 90篇 |
内科学 | 132篇 |
皮肤病学 | 3篇 |
神经病学 | 42篇 |
特种医学 | 8篇 |
外科学 | 141篇 |
综合类 | 9篇 |
一般理论 | 1篇 |
预防医学 | 43篇 |
药学 | 56篇 |
中国医学 | 7篇 |
肿瘤学 | 154篇 |
出版年
2021年 | 18篇 |
2020年 | 5篇 |
2019年 | 11篇 |
2018年 | 10篇 |
2017年 | 13篇 |
2016年 | 10篇 |
2015年 | 11篇 |
2014年 | 18篇 |
2013年 | 20篇 |
2012年 | 30篇 |
2011年 | 37篇 |
2010年 | 18篇 |
2009年 | 28篇 |
2008年 | 41篇 |
2007年 | 48篇 |
2006年 | 49篇 |
2005年 | 41篇 |
2004年 | 39篇 |
2003年 | 42篇 |
2002年 | 33篇 |
2001年 | 28篇 |
2000年 | 24篇 |
1999年 | 18篇 |
1998年 | 13篇 |
1997年 | 6篇 |
1996年 | 5篇 |
1995年 | 5篇 |
1994年 | 5篇 |
1992年 | 25篇 |
1991年 | 18篇 |
1990年 | 21篇 |
1989年 | 8篇 |
1988年 | 9篇 |
1987年 | 8篇 |
1986年 | 10篇 |
1985年 | 9篇 |
1984年 | 7篇 |
1983年 | 6篇 |
1980年 | 7篇 |
1979年 | 8篇 |
1978年 | 5篇 |
1974年 | 9篇 |
1973年 | 5篇 |
1972年 | 7篇 |
1971年 | 10篇 |
1970年 | 4篇 |
1969年 | 9篇 |
1968年 | 4篇 |
1967年 | 11篇 |
1966年 | 9篇 |
排序方式: 共有891条查询结果,搜索用时 31 毫秒
81.
Brandes JL Kudrow D Stark SR O'Carroll CP Adelman JU O'Donnell FJ Alexander WJ Spruill SE Barrett PS Lener SE 《JAMA》2007,297(13):1443-1454
Context Multiple pathogenic mechanisms may be involved in generating the migraine symptom complex, and multimechanism-targeted therapy may confer advantages over monotherapy. Objective To evaluate the efficacy and safety of a fixed-dose tablet containing sumatriptan succinate and naproxen sodium relative to efficacy and safety of each monotherapy and placebo for the acute treatment of migraine. Design, Setting, and Participants Two replicate, randomized, double-blind, single-attack, parallel-group studies conducted among 1461 (study 1) and 1495 (study 2) patients at 118 US clinical centers who were diagnosed as having migraine and received study treatment for a moderate or severe migraine attack. Interventions Patients were randomized in a 1:1:1:1 ratio to receive a single tablet containing sumatriptan, 85 mg, and naproxen sodium, 500 mg; sumatriptan, 85 mg (monotherapy); naproxen sodium, 500 mg (monotherapy); or placebo, to be used after onset of a migraine with moderate to severe pain. Main Outcome Measures Primary outcome measures included the percentages of patients with headache relief 2 hours after dosing, absence of photophobia, absence of phonophobia, and absence of nausea for the comparison between sumatriptannaproxen sodium and placebo, and the percentages of patients with sustained pain-free response for the comparison between sumatriptannaproxen sodium and each monotherapy. Results Sumatriptannaproxen sodium was more effective than placebo for headache relief at 2 hours after dosing (study 1, 65% vs 28%; P<.001 and study 2, 57% vs 29%; P<.001), absence of photophobia at 2 hours (58% vs 26%; P<.001 and 50% vs 32%; P<.001), and absence of phonophobia at 2 hours (61% vs 38%; P<.001 and 56% vs 34%; P<.001). The absence of nausea 2 hours after dosing was higher with sumatriptannaproxen sodium than placebo in study 1 (71% vs 65%; P = .007), but in study 2 rates of absence of nausea did not differ between sumatriptannaproxen sodium and placebo (65% vs 64%; P = .71). For 2- to 24-hour sustained pain-free response, sumatriptannaproxen sodium was superior at P<.01 (25% and 23% in studies 1 and 2, respectively) to sumatriptan monotherapy (16% and 14% in studies 1 and 2), naproxen sodium monotherapy (10% and 10% in studies 1 and 2), and placebo (8% and 7% in studies 1 and 2). The incidence of adverse events was similar between sumatriptannaproxen sodium and sumatriptan monotherapy. Conclusion Sumatriptan, 85 mg, plus naproxen sodium, 500 mg, as a single tablet for acute treatment of migraine resulted in more favorable clinical benefits compared with either monotherapy, with an acceptable and well-tolerated adverse effect profile. Trial Registration clinicaltrials.gov Identifiers: NCT00434083 (study 1); NCT00433732 (study 2) 相似文献
82.
83.
T. Feenstra M. S. Thøgersen E. Wieser A. Peschel M. J. Ball R. Brandes S. C. Satchell T. Stockner F. M. Aarestrup A. J. Rees R. Kain 《European journal of clinical microbiology & infectious diseases》2017,36(3):467-478
FimH-mediated adhesion of Escherichia coli to bladder epithelium is a prerequisite for urinary tract infections. FimH is also essential for blood-borne bacterial dissemination, but the mechanisms are poorly understood. The purpose of this study was to assess the influence of different FimH mutations on bacterial adhesion using a novel adhesion assay, which models the physiological flow conditions bacteria are exposed to. We introduced 12 different point mutations in the mannose binding pocket of FimH in an E. coli strain expressing type 1 fimbriae only (MSC95-FimH). We compared the bacterial adhesion of each mutant across several commonly used adhesion assays, including agglutination of yeast, adhesion to mono- and tri-mannosylated substrates, and static adhesion to bladder epithelial and endothelial cells. We performed a comparison of these assays to a novel method that we developed to study bacterial adhesion to mammalian cells under flow conditions. We showed that E. coli MSC95-FimH adheres more efficiently to microvascular endothelium than to bladder epithelium, and that only endothelium supports adhesion at physiological shear stress. The results confirmed that mannose binding pocket mutations abrogated adhesion. We demonstrated that FimH residues E50 and T53 are crucial for adhesion under flow conditions. The coating of endothelial cells on biochips and modelling of physiological flow conditions enabled us to identify FimH residues crucial for adhesion. These results provide novel insights into screening methods to determine the effect of FimH mutants and potentially FimH antagonists. 相似文献
84.
Seth A. Brodie Ge Li Donald Harvey Fadlo R. Khuri Paula M. Vertino Johann C. Brandes 《Oncotarget》2015,6(31):30773-30786
The mitotic checkpoint protein CHFR has emerged as a major mediator of taxane resistance in cancer. Here we show that CHFR''s PAR-binding zinc finger domain (PBZ) mediates a protein interaction with poly-ADP ribosylated PARP1 leading to stabilization of CHFR. Disruption of the CHFR-PARP1 interaction through either PARP1 shRNA-mediated knockdown or overexpression of a PBZ domain peptide induces loss of CHFR protein expression. In an attempt to exploit this observation therapeutically, and to develop compounds with synthetic lethality in combination with taxanes, we performed a high-throughput computational screen of 5,256,508 chemical structures against the published crystal structure of the CHFR PBZ domain to identify candidate small molecule CHFR protein-protein interaction inhibitors. The 10 compounds with the best docking scores (< −9.7) were used for further in vitro testing. One lead compound in particular, termed ‘A3’, completely disrupted the protein-protein interaction between CHFR and PARP1, resulting in the inhibition of mitotic checkpoint function, and led to therapeutic synergy with docetaxel in cell viability and colony formation assays. In mouse xenografts, i.p. administration of ‘A3’ led to a significant reduction in nuclear CHFR protein expression with a maximal effect 4 hours after administration, confirming relevant pharmacodynamics following the peak of ‘A3’ plasma concentration in vivo. Furthermore, combination of A3 and taxane led to significant reduction of implanted tumor size without increase in hematological, hepatic or renal toxicity. These findings provide a proof-of-principle that small molecule inhibition of CHFR PBZ domain interaction is a novel potential therapeutic approach to increase the efficacy of taxane-based chemotherapy in cancer. 相似文献
85.
Enrico Franceschi Mario Ermani Stefania Bartolini Marco Bartolotti Rosalba Poggi Giovanni Tallini Gianluca Marucci Antonio Fioravanti Alicia Tosoni Raffaele Agati Antonella Bacci Eugenio Pozzati Luca Morandi Damiano Balestrini Claudio Ghimenton Girolamo Crisi Alba A. Brandes 《Journal of neuro-oncology》2015,121(2):399-404
86.
The rapid expansion of novel technologies in cancer research over the past several years has led to a dramatically improved understanding of the molecular biology of lung cancer. As a consequence, novel targeted therapies are rapidly being developed. In this review, we summarize the most important molecular pathways in lung cancer and describe the clinical evidence for the development of therapies against these targets. 相似文献
87.
88.
89.
European Cooperative Crohn's Disease Study (ECCDS): colonoscopy 总被引:1,自引:0,他引:1
130 patients with Crohn's disease were colonoscopied in a multicenter trial. The obtained data were analyzed with respect to gathering information on the inflammation pattern, as well as on the importance and prognostic value of special lesions in Crohn's colitis. In 52 patients a second endoscopy was performed at the end of the 2-year study period. Ulcerations and aphthous lesions were the most common lesions, followed by pseudopolyps, cobblestone lesions and stenosis. In general, there was an increasing, distal gradient in the frequency of severe lesions. patients with Crohn's colitis alone had more signs of inflammation than patients with additional involvement of the small intestine. A segmental pattern was the most common form of inflammation. The group of patients (14%) with a continuous pattern did not deviate from the whole collective in clinical activity. In patients with previous resections, inflammation near the anastomosis was accompanied more often than not by stenosis. Patients with ulcerations had a rather short time since confirmation of the diagnosis. Cobblestone lesions and pseudopolyps correlated with short symptomatology. During the follow-up of the study, patients taking steroids or a combination with prednisolone and sulfasalazine seem to have better results than those under placebo or sulfasalazine alone, as regards the more severe symptoms. 相似文献
90.
I Herz A Assali A Solodky N S Simcha Brandes N Buto I Teplizky H Menkes E Rechavia D Hasdai T Ben-Gal Y Adler 《Catheterization and cardiovascular interventions》2000,49(4):384-388
To evaluate the feasibility of stenting without predilatation, we registered all interventional procedures over a 6-month period. Six hundred patients were registered, and 684 lesions were treated. Interventions were divided into four groups: stenting without predilatation (SWOP), 221 lesions (32.4%); primary stenting with predilatation (PDS), 161 lesions (23.5%); provisional stenting (PRS), 131 lesions (19.2%); and plain-old balloon angioplasty (POBA), 171 lesions (25%). Interventional strategy was at the discretion of the operator based on few simple angiographic criteria and his clinical judgment. Procedural success was similar in all stent groups. We conclude that when primary stenting is planned, about 60% of lesions can be treated by SWOP effectively with excellent procedural results and considerable cost saving. 相似文献